Home / Market News / $SCHP
fiscal.ai Corporate Catalyst Impact 75/100 ● negative

UBS Downgrades SCHOTT Pharma to 'Neutral' and Lowers Price Target

Nov 9, 2026, 1:05 PM UTC · Primary ticker $SCHP

UBS has downgraded SCHOTT Pharma's stock rating from 'Buy' to 'Neutral' and lowered its price target, citing concerns about decreased demand for glass syringes. This adjustment follows a revised forecast from a competitor, indicating a potentially challenging market environment for SCHOTT Pharma through fiscal year 2027/28.

UBS downgraded SCHOTT Pharma to 'Neutral' and cut its price target due to anticipated decreased demand for glass syringes, a core product. This revision was prompted by a competitor's (Stevanato) updated forecast, suggesting a broader industry trend rather than an isolated issue for SCHOTT Pharma. The downgrade implies a challenging outlook for SCHOTT Pharma's revenue and profitability through fiscal year 2027/28, potentially leading to short-term negative pressure on its stock. For traders, this signals a need to re-evaluate SCHOTT Pharma's growth prospects and consider potential downside risk, especially given the long-term nature of the demand concerns.

$SCHP negative Analyst downgrade and price target reduction
$STVN neutral Competitor whose revised forecast influenced downgrade
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.